zardaverine has been researched along with Malignant Melanoma in 1 studies
zardaverine: structure given in first source
zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nazir, M | 1 |
| Senkowski, W | 1 |
| Nyberg, F | 1 |
| Blom, K | 1 |
| Edqvist, PH | 1 |
| Jarvius, M | 1 |
| Andersson, C | 1 |
| Gustafsson, MG | 1 |
| Nygren, P | 1 |
| Larsson, R | 1 |
| Fryknäs, M | 1 |
1 other study available for zardaverine and Malignant Melanoma
| Article | Year |
|---|---|
Targeting tumor cells based on Phosphodiesterase 3A expression.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Colonic N | 2017 |